Glioblastoma multiforme (GBM) are devastating neoplasms with high invasive capacity. GBM has been difficult to study in vitro. Therapeutic progress is also limited by cellular heterogeneity within and between tumors. To address these challenges, we present an experimental model using human cerebral organoids as a scaffold for patient-derived glioblastoma cell invasion. By tissue clearing and confocal microscopy, we show that tumor cells within organoids extend a network of long microtubes, recapitulating the in vivo behavior of GBM. Single-cell RNAseq of GBM cells before and after co-culture with organoid cells reveals transcriptional changes implicated in the invasion process that are coherent across patient samples, indicating that GBM cells reactively upregulate genes required for their dispersion. Functional therapeutic targets are identified by an in silico receptor-ligand pairing screen detecting potential interactions between GBM and organoid cells. Taken together, our model has proven useful for studying GBM invasion and transcriptional heterogeneity in vitro, with applications for both pharmacological screens and patient-specific treatment selection at a time scale amenable to clinical practice.
Introduction
Glioblastoma (GBM) is the most frequent and most aggressive primary brain tumor 1, 2 . Despite decades of intensive research, average survival time remains at 12-15 months from diagnosis 3 . Surgical resection of GBM tumors is rarely complete because the tumor aggressively infiltrates the brain, with cells interconnecting via long membrane protrusions (microtubes) 4 . The resulting network enables multicellular communication through microtube-associated gap junctions, and increases tumor resistance to cell ablation and radiotherapy 5 . Moreover, glioblastoma cells interact with normal brain cells via soluble factors or direct cell-cell contacts to promote tumor proliferation and invasion 6 .
Two major challenges have impeded progress in the development of new GBM therapies. Firstly, there is increasing evidence for substantial genetic 7, 8 , epigenetic 9, 10 and transcriptional heterogeneity 11 between and within human tumors. Recent advances in single-cell RNA sequencing (scRNA-seq) technology have enabled the transcriptomic analysis of numerous tumor entities at the level of individual cells. However, in the case of GBM, resection of primary samples has resulted in limited insight into interactions between infiltrating tumor and normal brain cells, as isolation of neoplastic cells from the tumor periphery has proven challenging 12 .
How cellular heterogeneity of GBM cells and their interactions with normal brain cells relate to differences in proliferation or invasive capacity, which ultimately determine patient outcome, thus remains unknown.
A second challenge in the advancement of GBM therapies is the current lack of model systems to study defining properties of human GBM, especially invasion into the surrounding brain tissue. Previous in vitro models have suffered from limited physiological relevance or have been incompatible with the time scales for clinical decision-making 6 . Recent studies have shown that human cerebral organoids can be used as a platform for tumor cell transplantation or genetic engineering of tumors, enabling microscopic observation of tumor development [13] [14] [15] . However, tumor cell interactions with normal brain cells have not been addressed yet.
Here, we developed an experimental approach to study the interaction of GBM and normal brain cells of the neuronal lineage in vitro, on clinically relevant timescales of less than 4 weeks. We used iPSC-derived human cerebral organoids as a 3D scaffold for the invasion of patientderived GBM cells and analyzed tumor microtube development by tissue clearing, confocal microscopy and semi-automated quantification. In addition, we performed scRNA-seq of GBM cells before and after co-culture with organoid cells and identified a transcriptional program induced by the interactions between tumor and normal brain cells, suggesting potential therapeutic targets.
Results

iPSC-derived cerebral organoids provide a scaffold for glioblastoma invasion
To study glioblastoma invasion in a physiologically relevant 3D context, we adapted an established protocol for human iPSC-derived cerebral organoid development 16 to achieve streamlined and reproducible production of organoids. From 24 days of age, cerebral organoids were co-cultured with fluorescently labelled glioblastoma cells from four patient-derived cell lines (Fig. 1A and Supplementary Table 1) . Samples were fixed after three days and subjected to tissue clearing using the FRUIT protocol 17 , enabling the visualization of tumor invasion by confocal microscopy. We found that tumor cells from all four GBM patients readily attached to and invaded into the organoids (Fig. 1B) . Tumor cells formed protrusions reaching to other cells over short and long distances (Fig. 1B) , consistent with tumor microtube formation observed in vivo in mice 4 . GBM cells primarily invaded into the neuronal layers of the organoids, with little invasion into neural progenitor rosettes (Fig. 1B) . Organoids were then enzymatically released and co-cultured with GFP-labelled GBM cells for 3 days. Samples were embedded in Matrigel again for fixation, tissue clearing and confocal imaging. B) GFP-labelled tumor cells from all four GBM patients invade into cerebral organoids (left; scale bars, 250 µm) where they form short-range and long-range connections (middle, maximum intensity projections over ~200-250 µm depth; scale bars, 50 µm). Invasion is largely restricted to neuronal layers, outside of neural progenitor rosettes indicated by dotted lines (right; scale bars, 50 µm).
Tumor microtube formation recapitulates in vivo behavior of GBM cells
We developed a semi-automated image processing workflow to analyze the invasion process quantitatively ( Fig. 2A and Methods), which we applied to a total of 66 organoids (n=15-19 for each of the four patient GBM cell lines). We found that, for organoids of comparable sizes, the fraction of organoid volume taken up by tumor cells was similar across the four patient-derived cell lines ( Fig. 2B and Supplementary Fig. 1A ). The distribution of glioblastoma cells within organoids was assessed by calculating the distances between GFP + voxels across the same set of organoids. Tumor cells spread widely in all cases ( Supplementary Fig. 1B ). To quantify invasion depth, we compared the distribution of distances of GFP + voxels from the organoid surface across 12 similarly sized organoids for each patient-derived cell line. Invasion depths exceeded 100 µm in the majority of organoids (Fig. 2C) , with some cells detected at approximately 300 µm from the organoid surface. While migration depth of the most invasive cells (90 th percentile of invasion depth) was uncorrelated with organoid size, we observed that cells from patients F6 and F9 were less invasive than cells from patients F2 and F3 ( Fig. 2D and Supplementary Videos), suggesting that the in vitro model can reproduce intertumor heterogeneity in invasive behavior. By tracing membrane-bound cellular processes in images, we found that the number of microtubes per GBM cell ranged up to 6, with 2.2±0.1 microtubes on average (Fig. 2E) . We quantified how many of these microtubes ended at other GBM cells, and identified between 0 and 4 such putative intratumoral connections per GBM cell, with an average of 1.2±0.1 connections (Supplementary Fig. 1C µm long (Fig. 2F) . Consistent with our earlier observation of intertumoral heterogeneity of invasive capacity, we found that microtube lengths differed between cell lines (Fig. 2F) . Interestingly, cell lines with higher invasive capacity also showed longer microtubes. scRNA-seq reveals transcriptional heterogeneity between tumors and after co-culture with organoid cells
Our imaging results confirm that iPSC-derived cerebral organoids represent an effective model system for quantifying GBM invasion and tumor microtube formation in vitro. To further study heterogeneity of and interactions between GBM and organoid cells at the transcriptome level, we developed a more efficient workflow that could be applied on clinically relevant timescales and at higher throughput. In the modified assay, dissociated 7-day-old cerebral organoids were mixed with GBM cells at a 1:1 ratio, and grown in co-culture for 3 days (Fig. 3A) . GBM cells from all four patient-derived cell lines readily mixed with dissociated organoid cells ( Fig. 3B and Supplementary Fig. 2A ). With or without addition of GBM cells, dissociated organoid cells efficiently re-established the characteristic architecture of progenitor rosettes and neuronal layers observed in cerebral organoids, and membrane protrusions emanating from tumor cells were visible in all samples (Fig. 3C ). After 3 days of co-culture, mixed spheroids were dissociated and subjected to scRNA-seq. For comparison, we also dissociated and sequenced recomposed spheroids of organoid cells that had not been mixed with GBM cells, referred to as neural progenitor cells (NPCs) below, and GBM cells from all four patient-derived cell lines that had been grown separately as spheroids in the same culture medium (Fig. 3A) . Following pre-processing and quality control, we obtained 5,083 single-cell transcriptional profiles with approximately 1,400 genes detected per cell on average ( Supplementary Fig. 2B ). PCA-based clustering and 2D visualization by t-SNE maps revealed that GBM cells cultured alone clustered separately for each patient (clusters 5, 6, 7 and 9), confirming intertumoral heterogeneity (Fig. 3D ). This was also highlighted by differential expression of putative marker genes for GBM subtypes 18 across patient samples ( Supplementary Fig. 2C ). We further identified three clusters (clusters 0, 1 and 3) containing cells from the unmixed organoids as well as cells from all four mixed samples, and concluded that the latter represent the organoid cells in the mixed samples (Fig. 3D) . The remaining clusters (clusters 2, 4 and 8) contain GBM cells from patients F2, F3 and F9 after co-culture with organoid cells. Note that as only six such cells were identified in the mixed sample from patient F6, they were excluded from further analyses and not displayed here.
Mixing GBM and organoid cells leads to up-regulation of a shared set of genes across patients
Differential gene expression testing between GBM cell clusters from mixed and unmixed samples revealed hundreds of genes that were significantly up-or downregulated upon coculture with organoid cells (adjusted p-value < 0.05, log(fold change) > 0.15), and an overlap of 45 genes that were upregulated in all patients (Fig. 3E) . These included the homeobox transcription factor PAX6, normally expressed in forebrain neural stem cells; the gap junction protein alpha 1 (GJA1) coding for connexin-43, which connects tumor microtubes in GBM 4 ; glypican-3 (GPC3), a cell surface heparan sulfate proteoglycan and Wnt activator whose expression correlates with invasiveness of hepatocellular carcinoma 19 ; collagen COL4A5, an extracellular matrix constituent; and several lysosomal, vesicular and secretory proteins (Fig.  3F and Supplementary Table 2) . Gene set enrichment analysis of the 45 coherently upregulated genes confirmed that genes relating to growth regulation, neuronal migration, extracellular secretion and stimulus response were enriched in this group (Fig. 3G) . Our results thus show that interactions between GBM and organoid cells increase expression of genes required for GBM network formation and invasion. 
Potential ligand-receptor interactions between tumor cells and organoid cells
To investigate the nature of interactions between GBM and organoid cells, we considered the expression of 2,557 known ligand-receptor pairs 20 across our samples, comprising a total of 1,398 unique genes. Of these, 317 genes were expressed in our data, with approximately 13% expressed differentially between the same cell types in unmixed and mixed samples (Fig. 4A) . 
Normalised number of cell-cell interactions GPI  ITGAE  CALM2  TFRC  PKM  RPSA  TF  APOE  CD44  TFPI  ROBO2  COL4A6  KIDINS220  EDNRB  BCAN  VCAM1  PLAUR  ACVR2A  COL4A5  CANX  COL11A1  LAMA1  HSP90AA1  ITGB3BP  ADAM10  MDK  PTMA  PRSS23  LRP2  TNC  ADAM17  NRP2  DLK1  PSAP  SFRP1  CNTNAP2  EPHA7 NCAM1  CD46  GPI  ITGAE  CALM2  TFRC  PKM  RPSA  TF  APOE  CD44  TFPI  ROBO2  COL4A6  KIDINS220  EDNRB  BCAN  VCAM1  PLAUR  ACVR2A  COL4A5  CANX  COL11A1  LAMA1  HSP90AA1  ITGB3BP  ADAM10  MDK  PTMA  PRSS23  LRP2  TNC  ADAM17  NRP2  DLK1  PSAP  SFRP1  CNTNAP2  EPHA7  GPC3 GBM only ligand-receptor pair revealed a group of ligand-receptor pairs that were expressed at low levels in the tumor-only and NPC-only cultures, but presented many potential interactions between tumor cells and organoid cells in the mixed cultures (Fig. 4C) . These included several collagenintegrin interactions, glypican-3 binding to insulin-like growth factor 1 receptor (IGF1R) or the cell cycle regulator CD81, and non-canonical Notch signaling (DLK1/NOTCH1, DLK1/NOTCH2). Notably, despite the transcriptional heterogeneity we observed between patients, our approach detected consistently expressed potential interactions across all patient cell lines (Fig. 4C) . Gene set enrichment analysis showed that the ligand-receptor pairs expressed at high levels in co-cultured samples are enriched for invasion-related genes (Fig.  4D) . Specifically, putative interactions in which GBM cells present the ligand and NPCs the receptor are enriched for genes involved in neuron projection development and receptor binding, whereas ligand-receptor pairs communicating in the opposite direction are enriched for extracellular matrix proteins.
Discussion
Despite its enormous therapeutic and prognostic significance, efficient methods to characterize the process of GBM invasion into human brain at a quantitative or transcriptional level are currently lacking. In this study, we present an in vitro model system in which lentivirally labelled patient-derived GBM cells invade into human cerebral organoids. By tissue clearing and confocal imaging, our approach shows that tumor cells extend up to 450 µm long membrane-bound processes after three days of invasion, recapitulating the development of GBM microtubes that has been observed in resected primary tumors and replicated in vivo in mice 4 . Many of these processes terminate at distant tumor cells in our in vitro model, consistent with the development of an interconnected GBM network. By making GBM invasion experimentally accessible in vitro in a 3D tissue-like architecture, our experimental approach also enables the correlation of morphological phenotypes with transcriptional regulation by integration of imaging with single-cell sequencing. Here, scRNA-seq analysis of GBM and organoid cells separately or after co-culture revealed transcriptional changes induced by the interactions of tumor cells with their environment. Genes implicated in stimulus response, neuronal migration, secretion and extracellular matrix were coherently upregulated across all tumor samples when mixed with NPCs, indicating that GBM cells sense the presence of neuronal cells and reactively amplify the transcription of genes supporting their dispersion. Among the upregulated genes were GJA1 (coding for connexin 43), known to enable multicellular communication via gap junctions in GBM networks in vivo 4 , and GPC-3, which has received little attention in glioblastoma 21 but whose expression evidentially correlates with higher invasive capacity in hepatocellular carcinoma 19 , where it also confers oncogenicity by activating the IGF signaling pathway through IGF1R 22 .
Heterogeneity between and within GBM tumors has impeded therapeutic progress for decades 23 , with no targeted therapy available yet 24 . Consistently, our imaging data shows that GBM cells from different patients varied in their invasive capacity. While additional patient samples and more single-cell transcriptional profiles would be necessary to robustly link intertumoral differences in invasion behavior with specific transcriptional changes, our results corroborated the high degree of transcriptional heterogeneity between patients 11 . However, we also detected a coherent element of transcriptional changes upon GBM and organoid cell coculture indicating that targeting functional processes such as tumor microtube formation might improve therapeutic outcomes across patients. Our analysis of ligand-receptor pair expression identified candidate pairs that may contribute to the invasion process; further studies should explore the functional significance of these putative interactions.
The results presented here establish the biological relevance of our organoid-based experimental system and show that interactions between GBM and organoid cells result in transcriptional changes detected by scRNA-seq. In the future, we expect that our approach will further enable functional studies of GBM invasion that would be difficult or impossible to be conducted in vivo, including long-term imaging of network formation and multicellular communication. While we here used tissue clearing and confocal imaging for an end-point quantification of tumor invasion, GBM-invaded organoids are similarly amenable to live imaging by two-photon or light-sheet microscopy. By combining imaging with recent singlecell RNA sequencing methodologies that provide transcriptome data for greater cell numbers 25, 26 , and with other single-cell sequencing modalities such as chromatin accessibility sequencing 27 , our model could thus help resolve the functional, transcriptional and epigenetic factors that are associated with different invasion behaviors of GBM or other tumors into human brain. It also provides the basis for high-content drug screens to assess patient-specific drug action on tumor and healthy brain cells, thus helping to identify the most effective drug at clinically relevant timescales.
For scRNA-seq of co-cultured GBM and organoid cells, NPC spheroids were generated by inducing iPSCs AggreWell plates as described above. After 7 days, NPC spheroids and lentivirally labelled GBM cells were dissociated using Accutase (StemCell Technologies), mixed in a 1:1 ratio, and replated onto AggreWell plates at 1,000 cells per cavity in neural maintenance medium. After 3 days, mixed spheroids were dissociated using Accutase (StemCell Technologies), washed twice in PBS, and passed through a 20 µm cell strainer (PluriSelect).
Cell isolation and library preparation:
Single-cell suspensions were stained with Hoechst and Propidium Iodide (ReadyProbe Cell Viability Imaging Kit, Invitrogen) for 10 min at room temperature and cell numbers and viability were checked with a Countess automated cell counter (Thermo Fisher). Samples were discarded if cell viability was below 85%. The TakaraBio iCELL8 system and the associated Rapid Development Protocol (in-chip RT-PCR amplification) were used for single cell isolation, reverse transcription and cDNA amplification 29 . Briefly, cell suspensions were distributed into a nanowell chip containing oligo-dT primers with a unique barcode for every well. Chips were imaged using an automated fluorescence microscope and frozen at -80°C until further use. Nanowells occupied by single cells were identified using the CellSelect software and manually curated in order to exclude non-detected doublets or dead cells. After thawing frozen chips, 50 nl of RT/Amp solution was dispensed into selected nanowells (Master mix: 56 µl 5 M Betaine, 24 µl 25 mM dNTP mix (TakaraBio), 3.2 µl 1 M MgCl2 (Invitrogen), 8.8 µl 100 mM Dithiothreitol (TakaraBio), 61.9 µl 5x SMARTScribe™ first-strand buffer, 33.3 µl 2x SeqAmp™ PCR buffer, 4.0 µl 100 µM RT E5 Oligo, 8.8 µl 10 µM Amp primer (all TakaraBio), 1.6 µl 100% Triton X-100 (Acros), 28.8 µl SMARTScribe™ Reverse Transcriptase, 9.6 µl SeqAmp™ DNA Polymerase (TakaraBio)). After in-chip RT/Amp amplification (18 amplification cycles, in-chip RT/Amp Rapid Development protocol) inside a modified SmartChip Cycler (Bio-Rad), libraries were pooled, concentrated (DNA Clean and Concentrator−5 kit, Zymo Research) and purified using 0.6x Ampure XP beads. Concentration and quality of cDNA was assessed by a fluorometer (Qubit) and by electrophoresis (Agilent Bioanalyzer high sensitivity DNA chips). Next generation sequencing libraries were constructed using the Nextera XT kit (Illumina) following the manufacturer´s instructions. Final libraries were sequenced with the NextSeq 500 system in high-output mode (paired-end, 21 x 70 for v1, 24 x 67 for v2 chip).
scRNA-seq data analysis:
Pre-processing, quality control and normalization: For pre-processing of single-cell RNA-seq data, an automated in-house workflow based on Roddy (https://github.com/TheRoddyWMS/Roddy) was used. Read quality was evaluated using FastQC. iCELL8 library barcodes from the first 21 bp reads were assigned to the associated nanowell with the Je demultiplexing suite 30 . Remaining primer sequences, Poly-A/T tails and low-quality ends (<25) were trimmed using Cutadapt. Furthermore, since NextSeq (Illumina) encodes undetected bases as incorrect 'Gs' with high quality, Cutadapt's '-nextseq-trim' option was used for improved quality trimming. Trimmed reads were mapped to the reference genome hs37d5 (derived from the 1000 genomes project) using the STAR aligner. Mapped BAM files were quantified using featureCounts with reference annotation gencode v19. RNA-seq libraries that contained less than 150 detected genes or more than 15% mitochondrial reads were filtered out. Adapting a previously published approach 31 , aggregate expression for each gene across all cells was calculated as Ea = log(mean[Ej,1…n] + 1), where Ej is the counts-per-million expression value of the gene in cell j. 8,533 genes with Ea > 2 were retained for analysis.
Comparison of tumor cells from individual and co-cultured samples:
Filtered and normalized data of all patients was combined to identify NPCs and tumor cells in each sample. Using the Seurat package as implemented in R 26 , principal component analysis (PCA) was performed prior to clustering, and the 'FindClusters' function (with resolution = 0.4) was run on the first 9 principal components only. Results were visualized by tSNE 32 . Clusters containing cells from the NPC-only sample were identified as 'brain', whereas clusters containing only GBM cells were identified as 'tumor'. After manual splitting of one of the resulting clusters, we obtained 10 clusters representing brain cells (3 clusters), tumor cells from co-cultured samples, or tumor cells from unmixed samples. Differential expression between mixed and unmixed tumor cells was evaluated using the 'FindMarkers' function in Seurat. Gene set enrichment analysis 33 was performed by computing overlaps between identified gene signatures and Gene Ontology (GO_C5) gene sets derived from the Molecular Signature Database (MSigDB, https://software.broadinstitute.org/gsea/msigdb).
Analysis of ligand-receptor interactions:
Potential receptor-ligand pairings were analyzed using 2,557 previously published receptor-ligand pairs consisting of 1,398 unique genes 20 , of which 317 were expressed in our data. Adapting a previously published approach 34 , we constructed a cell-cell interaction matrix by summing for each pair of cells from the same sample the number of ligand-receptor pairs potentially connecting the pair, with one cell type expressing the receptor and the other the ligand (normalized expression cutoff >0.5). To identify ligandreceptor interactions with likely significance for the invasion process, we then considered each ligand-receptor pair in turn, and calculated the number of cell pairs connected by this ligand-receptor interaction for each possible cell type combination (tumor-tumor, brain-brain, tumor-brain), for each sample. The resulting interaction matrix was normalized to the maximum possible number of cell-cell interactions. To identify ligand-receptor pairs with coherent differential expression across patients, we considered only those ligand-receptor pairs with mean
